Anteris reports positive 30-day outcomes for medium-size DurAVR THV in EMBARK study

Anteris Technologies reported 30-day clinical and hemodynamic outcomes from its EMBARK study for the medium-size DurAVR transcatheter heart valve, showing a favorable profile with a large effective orifice area of 2.64 ± 0.19 cm2 and a single-digit mean pressure gradient of 6.17 ± 1.40 mmHg.

Detected & updated continuously · Source: Nebula